Corvus reports Q3 2026 results, outlines soquelitinib pipeline milestones for 2027

Corvus Pharmaceuticals reported third quarter 2026 financial results and a business update on November 5, 2026. The company said it is enrolling patients in the SIERRA1 Phase 2 randomized, blinded, placebo-controlled atopic dermatitis trial, anticipated to enroll approximately 200 patients across four cohorts of 50 patients each using soquelitinib doses of 200 mg once daily, 200 mg twice daily, and 400 mg once daily plus placebo, with a 12-week treatment period, a 90-day follow-up, and a primary endpoint of percent change in EASI score at Week 12 versus placebo.¹

In China, partner Angel Pharmaceuticals completed enrollment in cohort 1 (n=24, 100 mg twice per day, 200 mg once per day and placebo) of its Phase 1b atopic dermatitis trial, with results from that cohort anticipated in March 2027.¹

For hidradenitis suppurativa, Corvus said it is enrolling a Phase 1b trial designed for up to 25 patients with moderate to severe HS, all receiving 200 mg twice daily for 12 weeks followed by a 90-day treatment-free follow-up; the primary endpoint is safety and tolerability, with a key efficacy endpoint of HiSCR 50/75 at week 12, and initial data anticipated in 1H 2027.¹ The company also said it plans to initiate a Phase 2 asthma trial by Q1 2027, while Angel Pharma anticipates starting its own Phase 2 asthma trial in Q2 2027.¹

On the ALPS program with NIAID, Corvus reported three patients treated in the Phase 2 trial have each completed 360 days of treatment at 200 mg twice per day, with no grade 3 or 4 adverse events, no therapy interruptions, and all three discontinuing background medications including steroids while reporting improvement in ALPS-related symptoms.¹

In PTCL, the company said it continues enrolling a registrational Phase 3 trial anticipated to include 150 relapsed/refractory PTCL patients, comparing soquelitinib to physicians' choice of belinostat or pralatrexate, with progression-free survival as the primary endpoint.¹

Financially, Corvus reported cash, cash equivalents and marketable securities of $202.9 million as of September 30, 2026, up from $56.8 million at year-end 2025, including about $189.4 million in net proceeds from a January 23, 2026 financing, with current plans expected to fund operations into the second quarter of 2028.¹ R&D expenses rose to $17.8 million from $8.5 million year over year, and net loss was $20.3 million versus $10.2 million a year earlier.¹